-
The 2025 HDBuzz Prize for Young Science Writers Is Open!
Latest News
-
Huntington's Disease Therapeutics Conference 2024 – Day 3
HDBuzz is back for the last day of the CHDI HD Therapeutics Conference: Thursday February 29th in Palm Springs, California. This article summarizes our real-time updates of the conference in community-friendly language. From genes to medicines The morning session will focus on how human genetics is driving the development of therapeutics. āGenetic modifiersā are genes…
-
Huntington's Disease Therapeutics Conference 2024 – Day 2
HDBuzz is back for Day 2 of the CHDI HD Therapeutics Conference: Wednesday February 28th in Palm Springs, California. This article summarizes our real-time updates of the conference in community-friendly language. Itās a brain disease This morningās session is titled āItās a brain diseaseā and will feature talks about BRAINSSSS! HD scientists are a bit…
-
Huntington's Disease Therapeutics Conference 2024 – Day 1
Check out research updates from Day 1 of the 2024 HD Therapeutics Conference #HDTC2024
-
CRISPR-based drugs: one giant leap for mankind
Casgevy is the first CRISPR-based drug to make its way through the approval process, all but curing Sickle Cell Disease and itās paving the way for similar drugs targeting other diseases. Is Huntingtonās disease next?
-
Steady progress from uniQure – promising data to end the year
uniQure ushered in the end of the year by releasing some promising data from their huntingtin-lowering gene therapy trials
-
Putting it in print: GENERATION HD1 study results published
Data from GENERATION HD1, the Phase 3 clinical trial testing the huntingtin-lowering drug tominersen, have just been published in a scientific journal. The trial ended a while back, so why is this an important milestone, and whatās next?
-
Regulating repetition: Gaining control of CAG repeats could slow progression of Huntingtonās disease
Many diseases are caused by repetitive DNA sequences. Understanding the regulation of those repetitive sequences may hold the key for unlocking therapeutics for Huntingtonās disease. A team from Toronto has just advanced our understanding.
-
Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD
The HD pipeline is rich and varied. Let's talk about some out-of-the-box approaches for developing drugs for HD that don't involve huntingtin lowering.
-
Getting to the Root of Huntington's Disease: A Plant-Based Approach
Researchers used plants to study how to stop the Huntingtonās disease protein from forming toxic clumps
-
Could halting CAG expansions be a new treatment for HD?
The gene MSH3 is getting a lot of attention in HD research lately. New findings suggest MSH3 lowering could halt CAG repeat expansions, offering a new therapeutic avenue.